Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Multicenter Study

NCT05427305 is registered in ClinicalTrials.gov with BioDlink Biopharm Co., Ltd. as lead sponsor.

NCT NCT05427305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05427305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Multicenter Study
Lead sponsor
BioDlink Biopharm Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2017
Completion date
March 24, 2020
Enrollment
549 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy